ArticleCost effectiveness and resource allocation : C/E2024
Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran.
Yalda Metghalchi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.